Keros Therapeutics (NASDAQ:KROS) Rating Reiterated by Truist Financial

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating reaffirmed by stock analysts at Truist Financial in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $100.00 price objective on the stock. Truist Financial’s target price would indicate a potential upside of 123.96% from the company’s current price.

A number of other equities research analysts also recently weighed in on KROS. William Blair reissued an “outperform” rating on shares of Keros Therapeutics in a research report on Wednesday, February 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Keros Therapeutics in a research report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Keros Therapeutics in a report on Thursday, February 29th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $86.00.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $44.65 on Tuesday. Keros Therapeutics has a 52 week low of $27.02 and a 52 week high of $73.00. The firm has a market capitalization of $1.61 billion, a PE ratio of -8.67 and a beta of 1.24. The business’s 50-day simple moving average is $53.02 and its 200-day simple moving average is $53.79.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.12. The business had revenue of $0.08 million during the quarter. During the same period last year, the company earned ($1.26) earnings per share. The company’s revenue for the quarter was down 97.3% compared to the same quarter last year. Research analysts forecast that Keros Therapeutics will post -4.97 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in Keros Therapeutics by 356.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock valued at $138,000 after buying an additional 2,702 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the last quarter. Arizona State Retirement System acquired a new stake in Keros Therapeutics in the fourth quarter worth about $231,000. Bayesian Capital Management LP bought a new stake in Keros Therapeutics during the 1st quarter worth about $267,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in Keros Therapeutics by 117.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after purchasing an additional 2,822 shares during the period. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.